PTC Therapeutics Inc (PTCT) - Net Assets
Based on the latest financial reports, PTC Therapeutics Inc (PTCT) has net assets worth $-205.31 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.91 Billion) and total liabilities ($3.12 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PTC Therapeutics Inc (PTCT) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-205.31 Million |
| % of Total Assets | -7.05% |
| Annual Growth Rate | N/A |
| 5-Year Change | -14377.68% |
| 10-Year Change | -271.69% |
| Growth Volatility | 6955.4 |
PTC Therapeutics Inc - Net Assets Trend (2004–2025)
This chart illustrates how PTC Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of PTC Therapeutics Inc for the complete picture of this company's asset base.
Annual Net Assets for PTC Therapeutics Inc (2004–2025)
The table below shows the annual net assets of PTC Therapeutics Inc from 2004 to 2025. For live valuation and market cap data, see PTCT market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-205.31 Million | +81.30% |
| 2024-12-31 | $-1.10 Billion | -34.15% |
| 2023-12-31 | $-818.55 Million | -135.84% |
| 2022-12-31 | $-347.09 Million | -24236.72% |
| 2021-12-31 | $1.44 Million | -99.70% |
| 2020-12-31 | $481.98 Million | -18.90% |
| 2019-12-31 | $594.33 Million | +69.46% |
| 2018-12-31 | $350.73 Million | +124.20% |
| 2017-12-31 | $156.44 Million | +30.82% |
| 2016-12-31 | $119.58 Million | -59.93% |
| 2015-12-31 | $298.47 Million | 0.00% |
| 2014-12-31 | $298.47 Million | +118.59% |
| 2013-12-31 | $136.54 Million | +811.36% |
| 2012-12-31 | $-19.19 Million | +91.96% |
| 2011-12-31 | $-238.60 Million | -721.35% |
| 2005-12-31 | $38.40 Million | +10.94% |
| 2004-12-31 | $34.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to PTC Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 296422900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $80.00K | % |
| Other Comprehensive Income | $10.50 Million | % |
| Other Components | $2.75 Billion | % |
| Total Equity | $-205.31 Million | 100.00% |
PTC Therapeutics Inc Competitors by Market Cap
The table below lists competitors of PTC Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GEM CO. LTD SP.GDR/10 A
F:3730
|
$5.40 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
$5.40 Billion |
|
Keda Clean Energy Co Ltd
SHG:600499
|
$5.40 Billion |
|
Home BancShares Inc
NYSE:HOMB
|
$5.40 Billion |
|
Sinopec Oilfield Service Corp
SHG:600871
|
$5.39 Billion |
|
Credit Acceptance Corporation
NASDAQ:CACC
|
$5.39 Billion |
|
Jfrog Ltd
NASDAQ:FROG
|
$5.39 Billion |
|
BRF SA ADR
NYSE:BRFS
|
$5.38 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PTC Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,098,071,000 to -205,313,000, a change of 892,758,000.
- Net income of 682,644,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 36,387,000.
- Other factors increased equity by 173,727,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $682.64 Million | +332.49% |
| Other Comprehensive Income | $36.39 Million | +17.72% |
| Other Changes | $173.73 Million | +84.62% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares PTC Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-10.08 | $65.15 | x |
| 2012-12-31 | $-0.81 | $65.15 | x |
| 2013-12-31 | $10.64 | $65.15 | x |
| 2014-12-31 | $9.46 | $65.15 | x |
| 2015-12-31 | $8.88 | $65.15 | x |
| 2016-12-31 | $3.51 | $65.15 | x |
| 2017-12-31 | $3.99 | $65.15 | x |
| 2018-12-31 | $7.53 | $65.15 | x |
| 2019-12-31 | $10.10 | $65.15 | x |
| 2020-12-31 | $7.30 | $65.15 | x |
| 2021-12-31 | $0.02 | $65.15 | x |
| 2022-12-31 | $-4.84 | $65.15 | x |
| 2023-12-31 | $-10.94 | $65.15 | x |
| 2024-12-31 | $-14.29 | $65.15 | x |
| 2025-12-31 | $-2.32 | $65.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PTC Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 39.44%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-2459.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | 31.23% | 2.24x | 0.00x | $54.76 Million |
| 2012 | 0.00% | -91.16% | 2.20x | 0.00x | $-24.32 Million |
| 2013 | -37.77% | -164.63% | 0.21x | 1.11x | $-65.23 Million |
| 2014 | -31.41% | -408.28% | 0.07x | 1.12x | $-123.60 Million |
| 2015 | -57.11% | -463.60% | 0.10x | 1.23x | $-200.29 Million |
| 2016 | -118.84% | -171.83% | 0.31x | 2.25x | $-154.07 Million |
| 2017 | -50.50% | -40.64% | 0.50x | 2.50x | $-94.64 Million |
| 2018 | -36.52% | -48.38% | 0.24x | 3.19x | $-163.15 Million |
| 2019 | -42.33% | -81.95% | 0.19x | 2.73x | $-311.01 Million |
| 2020 | -90.91% | -115.07% | 0.17x | 4.58x | $-486.36 Million |
| 2021 | -36432.61% | -97.27% | 0.28x | 1347.74x | $-524.04 Million |
| 2022 | 0.00% | -80.00% | 0.41x | 0.00x | $-524.31 Million |
| 2023 | 0.00% | -66.81% | 0.49x | 0.00x | $-544.75 Million |
| 2024 | 0.00% | -45.03% | 0.47x | 0.00x | $-253.49 Million |
| 2025 | 0.00% | 39.44% | 0.59x | 0.00x | $703.18 Million |
Industry Comparison
This section compares PTC Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PTC Therapeutics Inc (PTCT) | $-205.31 Million | 0.00% | N/A | $5.39 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervo… Read more